MeiraGTx/$MGTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About MeiraGTx
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
- Ticker
- $MGTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 393
- Headquarters
- New York, United States
- Website
- www.meiragtx.com
MeiraGTx Metrics
BasicAdvanced
$997M
11.06
$0.94
1.27
-
Price and volume
Market cap
$997M
Beta
1.27
52-week high
$15.35
52-week low
$6.62
Average daily volume
957K
Financial strength
Current ratio
3.758
Quick ratio
3.226
Long term debt to equity
0.51
Total debt to equity
0.521
Interest coverage (TTM)
14.75%
Profitability
EBITDA (TTM)
196.131
Gross margin (TTM)
97.95%
Net profit margin (TTM)
19.87%
Operating margin (TTM)
46.30%
Effective tax rate (TTM)
2.91%
Revenue per employee (TTM)
$1,010,000
Management effectiveness
Return on assets (TTM)
38.65%
Return on equity (TTM)
72.17%
Valuation
Price to earnings (TTM)
11.062
Price to revenue (TTM)
2.186
Price to book
4.54
Price to tangible book (TTM)
4.54
Price to free cash flow (TTM)
-61.322
Free cash flow yield (TTM)
-1.63%
Free cash flow per share (TTM)
-0.169
Growth
Revenue change (TTM)
948.35%
Earnings per share change (TTM)
-146.17%
3-year revenue growth (CAGR)
295.98%
3-year earnings per share growth (CAGR)
-28.32%
What the Analysts think about MeiraGTx
Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.
Analyst projections of the future price of MeiraGTx stock.
Bulls say / Bears say
Bota-vec gives the company a potential near-term route to market: MeiraGTx has reacquired the X-linked retinitis pigmentosa therapy and plans global regulatory filings in 2026, with a possible launch in 2027 if approved. (MeiraGTx)
Bota-vec failed to meet the primary endpoint in its Phase 3 LUMEOS trial. MeiraGTx is pursuing filings using the wider data package, but the miss leaves a material question over whether regulators will approve it. (BioSpace)
The September share offering issued 11.1 million new shares at $9 each, diluting existing holders. MeiraGTx also expects substantial future losses as it funds development and potential launches, so further financing may be needed. (StockTitan, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2026.
MeiraGTx Financial Performance
Revenues and expenses
MeiraGTx Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing MeiraGTx
AllUSDGBPEUR
Fund name | Fund size | $MGTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.